Q3 Earnings Estimate for Moderna Issued By Leerink Partnrs

Key Points

• Leerink Partners has raised its Q3 2025 EPS estimate for Moderna to ($1.95) from a previous estimate of ($2.29), indicating a slight improvement in projected losses.
• The stock has a current consensus rating of "Hold" with a price target averaging $39.93.
• Moderna's recent earnings report revealed a 41.1% decline in quarterly revenue year-over-year, with an EPS of ($2.13), exceeding analyst expectations of ($2.99).

Moderna, Inc. (NASDAQ:MRNA - Free Report) - Leerink Partnrs upped their Q3 2025 EPS estimates for shares of Moderna in a research note issued to investors on Wednesday, October 15th. Leerink Partnrs analyst M. Foroohar now expects that the company will post earnings per share of ($1.95) for the quarter, up from their previous estimate of ($2.29). The consensus estimate for Moderna's current full-year earnings is ($9.61) per share. Leerink Partnrs also issued estimates for Moderna's Q4 2025 earnings at ($3.38) EPS, FY2025 earnings at ($9.98) EPS, FY2026 earnings at ($7.73) EPS, FY2027 earnings at ($4.65) EPS and FY2028 earnings at ($2.78) EPS.

Other equities research analysts have also issued research reports about the company. Weiss Ratings restated a "sell (e+)" rating on shares of Moderna in a research report on Wednesday, October 8th. Morgan Stanley upped their price target on shares of Moderna from $31.00 to $32.00 and gave the company an "equal weight" rating in a research report on Friday, October 10th. Evercore ISI set a $32.00 price target on shares of Moderna in a report on Friday, August 1st. JPMorgan Chase & Co. set a $26.00 price objective on shares of Moderna in a research note on Friday, August 1st. Finally, Citigroup assumed coverage on Moderna in a research report on Friday, August 1st. They set a "neutral" rating and a $40.00 target price for the company. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, twelve have issued a Hold rating and five have given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus price target of $39.93.

Moderna Stock Performance

Moderna stock opened at $27.14 on Friday. Moderna has a 52 week low of $23.15 and a 52 week high of $57.69. The stock has a market capitalization of $10.60 billion, a P/E ratio of -3.60 and a beta of 2.01. The stock has a fifty day moving average of $25.91 and a 200-day moving average of $27.10.

Moderna (NASDAQ:MRNA - Get Free Report) last released its earnings results on Friday, August 1st. The company reported ($2.13) earnings per share for the quarter, topping the consensus estimate of ($2.99) by $0.86. The firm had revenue of $142.00 million during the quarter, compared to analysts' expectations of $116.26 million. Moderna had a negative return on equity of 25.96% and a negative net margin of 94.31%.The company's quarterly revenue was down 41.1% on a year-over-year basis. During the same period in the prior year, the company earned ($3.33) earnings per share. Moderna has set its FY 2025 guidance at EPS.

Institutional Trading of Moderna

Hedge funds and other institutional investors have recently bought and sold shares of the business. GAMMA Investing LLC lifted its stake in shares of Moderna by 149.8% in the first quarter. GAMMA Investing LLC now owns 7,926 shares of the company's stock valued at $225,000 after buying an additional 4,753 shares in the last quarter. Assenagon Asset Management S.A. raised its holdings in shares of Moderna by 11.0% in the 1st quarter. Assenagon Asset Management S.A. now owns 16,623 shares of the company's stock worth $471,000 after acquiring an additional 1,645 shares during the last quarter. Exchange Traded Concepts LLC lifted its position in Moderna by 17.4% in the 1st quarter. Exchange Traded Concepts LLC now owns 30,693 shares of the company's stock valued at $870,000 after acquiring an additional 4,556 shares in the last quarter. Janney Montgomery Scott LLC boosted its stake in Moderna by 37.1% during the 1st quarter. Janney Montgomery Scott LLC now owns 13,825 shares of the company's stock valued at $392,000 after purchasing an additional 3,744 shares during the last quarter. Finally, QRG Capital Management Inc. boosted its stake in Moderna by 16.1% during the 1st quarter. QRG Capital Management Inc. now owns 8,274 shares of the company's stock valued at $235,000 after purchasing an additional 1,150 shares during the last quarter. Institutional investors own 75.33% of the company's stock.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.